Evidence map›Paper›PMID 39865094›Full record

ArticleNature communications2025

Standard operating procedure combined with comprehensive quality control system for multiple LC-MS platforms urinary proteomics.

Xiang Liu, Haidan Sun, Xinhang Hou, Jiameng Sun, Min Tang, Yong-Biao Zhang, Yongqian Zhang, Wei Sun, Chao Liu, Urine Test Sample Working Group

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Biomarkers of Cardiac Metabolic Flexibility in Health, HFrEF and HFpEF.International journal of molecular sciences · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiang Liu *School of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.
Haidan Sun *Proteomics Center, Core Facility of Instrument, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
Xinhang Hou *School of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.
Jiameng SunProteomics Center, Core Facility of Instrument, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China.
Min TangSchool of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.
Yong-Biao ZhangSchool of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China.ORCID http://orcid.org/0000-0002-2764-2148
Yongqian ZhangSchool of Medical Technology, Beijing Institute of Technology, Beijing, China.ORCID http://orcid.org/0000-0003-1047-3701
Wei SunProteomics Center, Core Facility of Instrument, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, School of Basic Medicine Peking Union Medical College, Beijing, China. sunwei@ibms.pumc.edu.cn.
Chao LiuSchool of Biological Science and Medical Engineering & School of Engineering Medicine, Beihang University, Beijing, China. liuchaobuaa@buaa.edu.cn.ORCID http://orcid.org/0000-0002-5286-6944
Urine Test Sample Working Group

Funding

National Natural Science Foundation of China (National Science Foundation of China) 31901039National Natural Science Foundation of China (National Science Foundation of China) 32171442National Natural Science Foundation of China (National Science Foundation of China) 82170524
6 · The paper itself

Abstract

Urinary proteomics is emerging as a potent tool for detecting sensitive and non-invasive biomarkers. At present, the comparability of urinary proteomics data across diverse liquid chromatography-mass spectrometry (LC-MS) platforms remains an area that requires investigation. In this study, we conduct a comprehensive evaluation of urinary proteome across multiple LC-MS platforms. To systematically analyze and assess the quality of large-scale urinary proteomics data, we develop a comprehensive quality control (QC) system named MSCohort, which extracted 81 metrics for individual experiment and the whole cohort quality evaluation. Additionally, we present a standard operating procedure (SOP) for high-throughput urinary proteome analysis based on MSCohort QC system. Our study involves 20 LC-MS platforms and reveals that, when combined with a comprehensive QC system and a unified SOP, the data generated by data-independent acquisition (DIA) workflow in urine QC samples exhibit high robustness, sensitivity, and reproducibility across multiple LC-MS platforms. Furthermore, we apply this SOP to hybrid benchmarking samples and clinical colorectal cancer (CRC) urinary proteome including 527 experiments. Across three different LC-MS platforms, the analyses report high quantitative reproducibility and consistent disease patterns. This work lays the groundwork for large-scale clinical urinary proteomics studies spanning multiple platforms, paving the way for precision medicine research.

Indexed as

Mass SpectrometryProteomeProteomicsUrinalysisChromatography, LiquidColorectal NeoplasmsFemaleHumansLiquid Chromatography-Mass SpectrometryMaleQuality ControlReproducibility of ResultsTandem Mass SpectrometryProteome

Identifiers

PMID39865094
PMCPMC11770173

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.